Zhuhai Kerui Biotechnology: difference between revisions
Diff·revision 6 → 7·09:09, 9 Jul 2025
Difference between revision 6 and revision 7 of Zhuhai Kerui Biotechnology. 5 lines changed; the page grew by 678 bytes.
| Revision 6 — 11:45, 30 Jun 2025 ForgeryFinder (talk) add the how-to-request-a-batch-record sentence to §Ordering and availability 4,713 bytes +519 | Revision 7 — 09:09, 9 Jul 2025 DiagramDelphine (talk) split §Operations from §Product range 5,391 bytes +678 | ||
|---|---|---|---|
| 1 | {{Infobox organisation | 1 | {{Infobox organisation |
| 2 | | name = Zhuhai Kerui Biotechnology Co., Ltd. | 2 | | name = Zhuhai Kerui Biotechnology Co., Ltd. |
| + | 3 | | image = facility.svg | |
| + | 4 | | caption = Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki. | |
| 3 | | Legal name = Zhuhai Kerui Biotechnology Co., Ltd. | 5 | | Legal name = Zhuhai Kerui Biotechnology Co., Ltd. |
| 4 | | Trading name = KP | 6 | | Trading name = KP |
| ⋮ | ⋮ | ||
| 28 | Reports describe lyophilised material in crimped glass vials with a batch certificate reporting purity, appearance and, in most of the submitted set, a water content.{{r|reports}} Insulated packaging with a gel pack is described for the incretin lines. | 30 | Reports describe lyophilised material in crimped glass vials with a batch certificate reporting purity, appearance and, in most of the submitted set, a water content.{{r|reports}} Insulated packaging with a gel pack is described for the incretin lines. |
| 29 | 31 | ||
| + | 32 | One documentation practice recorded across several reports is worth noting: certificates in this set have named the analytical method and column, which is uncommon. A purity figure with a stated method is more useful than one without, because [[Area percent purity|area percent]] depends on the separation that produced it.{{r|usp1503}} | |
| + | 33 | ||
| 30 | == References == | 34 | == References == |
| 31 | {{reflist}} | 35 | {{reflist}} |
| ⋮ | ⋮ | ||
| 34 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> | 38 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> |
| 35 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 39 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| + | 40 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | |
| 36 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 41 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 37 | 42 |